Nymox Pharmaceutical Corporation Stock Nasdaq
Equities
CA67076P1027
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 29.51M |
---|---|---|---|---|---|
Net income 2021 | -12M | Net income 2022 | -6M | EV / Sales 2021 | - |
Net cash position 2021 | 439K | Net cash position 2022 | 1.23M | EV / Sales 2022 | - |
P/E ratio 2021 |
-8.5
x | P/E ratio 2022 |
-4.39
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.95% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Director/Board Member | - | 23-03-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 06-06-07 |
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Director/Board Member | 88 | 15-06-30 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |